Drug Trial Radar · NCT04720378
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
Last checked: Nov 19, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
May 30, 2021
Primary completion
May 3, 2022
Study completion May 3, 2022
Sponsor
- Lead sponsor
- Noveome Biotherapeutics, formerly StemnionIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Biotech
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.
Conditions
- Cytokine Release Syndrome
Interventions
ST266Biological
1X ST266
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment-Emergent Adverse EventsTime frame: 3 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Innovative Research of West Florida
Clearwater, Florida
Great Lakes Clinical Trials
Chicago, Illinois
WR-ClinSearch, LLC
Chattanooga, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.